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CONTEXT: Despite multiple attempts to document and
quantify the danger of venous thromboembolism (VTE)
following prolonged travel, there is still uncertainty
about the magnitude of risk and what can be done to
lower it.
OBJECTIVES: To review the methodologic strength of
the literature, estimate the risk of travel-related VTE,
evaluate the efficacy of preventive treatments, and de-
velop evidence-based recommendations for practice.
DATA SOURCES: Studies identified from MEDLINE
from 1966 through December 2005, supplemented by
a review of the Cochrane Central Registry of Controlled
Trials, the Database of Abstracts of Reviews of Effects,
and relevant bibliographies.
STUDY SELECTION: We included all clinical studies
that either reported primary data concerning travel as a
risk factor for VTE or tested preventive measures for
travel-related VTE.
DATA EXTRACTION AND ANALYSIS: Two reviewers
reviewed each study independently to assess inclusion
criteria, classify research design, and rate methodologic
features. The effect of methodologic differences, VTE
risk, and travel duration on VTE rate was evaluated
using a logistic regression model.
DATA SYNTHESIS: Twenty-four published reports,
totaling 25 studies, met inclusion criteria (6 case-
control studies, 10 cohort studies, and 9 randomized
controlled trials). Method of screening for VTE [screen-
ing ultrasound compared to usual clinical care, odds
ratio (OR) 390], outcome measure [all VTE compared to
pulmonary embolism (PE) only, OR 21], duration of
travel (<6 hours compared to 6–8 hours, OR 0.011), and
clinical risk (“higher” risk travelers compared to “lower,”
OR 3.6) were significantly related to VTE rate. Clinical
VTE after prolonged travel is rare [27 PE per million
flights diagnosed through usual clinical care, 0.05%
symptomatic deep venous thrombosis (DVT) diagnosed
through screening ultrasounds], but asymptomatic
thrombi of uncertain clinical significance are more
common. Graduated compression stockings prevented
travel-related VTE (P<0.05 in 4 of 6 studies), aspirin did
not, and low-molecular-weight heparin (LMWH) showed
a trend toward efficacy in one study.
CONCLUSIONS: All travelers, regardless of VTE risk,
should avoid dehydration and frequently exercise leg
muscles. Travelers on a flight of less than 6 hours and
those with no known risk factors for VTE, regardless of
the duration of the flight, do not need DVT prophylaxis.
Travelers with 1 or more risk factors for VTE should
consider graduated compression stockings and/or
LMWH for flights longer than 6 hours.
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INTRODUCTION
In 2003, 104 million passengers flew into or out of the United
States on transoceanic flights.
1 By 2015, this number will
almost double. While in transit, some of these passengers will
develop deep venous thrombosis (DVT) or pulmonary embolism
(PE).
2–4 Despite multiple attempts to quantify the danger, there
is still uncertainty about the risk of venous thromboembolism
(VTE) from prolonged travel, which travelers should receive VTE
prophylaxis, and what prophylactic measures should be used.
We performed a systematic review of this literature to address
the following questions: (1) What are the methodologic
strengths and weaknesses in this literature? (2) What is the
risk for travel-related VTE? (3) Are there effective preventive
measures? Using our findings, we propose evidence-based
recommendations for practice.
METHODS
Using the MEDLINE database from 1966 through December
2005, we searched for articles evaluating human subjects that
either reported primary data concerning the risk of travel for VTE
or tested preventive measures for travel-related VTE. Our search
included the MESH headings thromboembolism, thrombosis,
venous thrombosis, thrombophlebitis,a n dpulmonary embolism.
We also searched under the MESH headings travel, aerospace
medicine, aviation,a n dtransportation,a n dt h et e x tw o r d sflight
and flying. We then combined the 2 searches into an initial set of
465 articles. We sought additional articles by performing the
same search strategy in the Cochrane Central Registry of
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107Controlled Trials and the Database of Abstracts of Reviews of
Effects.
5 We then reviewed the references from relevant articles
in the initial set for articles not already identified. We included
case-control studies, cohort studies, and randomized controlled
trials (RCTs), but excluded case reports, abstracts, and subgroup
analyses of previously published studies.
Two of 3 authors (RS, DMB, and JTP) reviewed each study
independently to determine whether it met inclusion criteria,
classified it according to research design, and evaluated it for
methodologic strength. The ratings of the 2 reviewers were
compared and discrepancies were resolved by discussion to
achieve consensus. To evaluate methodologic strength, we
used 8 standards adapted from previous research on the
natural history of disease.
6,7 These standards are described
in the Appendix.
STATISTICAL ANALYSIS
For each cohort study group and RCT study arm, we recorded
number of subjects, number of subjects with VTE, VTE
outcome (PE, DVT, or both), travel duration (mean of less than
6 hours, mean of 6 to 8 hours, and mean greater than 8 hours),
treatment (yes/no), method of screening for VTE (usual clinical
care or screening ultrasound after travel) and clinical VTE risk
of travelers (lower or higher). We then examined associations
between these variables and VTE outcomes in untreated
travelers using the 26 study arms where there was both travel
and no intervention (treatment=no). Because the dependent
variable was dichotomous (whether or not each participant
had a VTE), we concluded that the natural distributional
assumption was the binomial distribution. Because we only
had summary data on groups rather than data on individual
subjects, we used the total number of subjects in each group
and the number of those with VTE to define a grouped binary
data structure. We then fitted a logistic regression model to
the data, where the coefficients of regression were log odds
ratios (LOR). These coefficients were related to the dependent
variable, VTE rate (r), by 2 transformations. The first was a
transformation to an odds ratio (OR) and the second to a
logarithm [LOR=log(r/(1−r)].
8,9 This method allows for a more
realistic distributional assumption for the dependent variable
than the normal distribution, accounts for different sample
sizes of the studies, has more statistical power, allows
independent variables to be incorporated into the model,
estimates effect of those variables on the dependent variable,
and decreases heterogeneity. We used SAS/STAT software,
version 9.1, to fit the models and estimate the parameters
(PROC GENMOD).
RESULTS
Descriptions of the Selected Studies
The search strategy identified 24 publications including 25
studies that met criteria for inclusion in this review.
10–33 There
were 6 case-control studies, 10 cohort studies, and 9 RCTs,
with 1 article including the results of both a cohort study and
a RCT.
18
The 6 case-control studies, described in Table 1, ranged in
size from 207
14 to 988 subjects
12 and were from 4 different
countries. Five of the 6 investigated risk from any form of
travel,
11–15 while 1 limited its focus to air travel.
16 The 10
cohort studies, described in Table 2, ranged in size from 320
19
to more than 135 million subjects
17 and were performed in 9
countries. All investigated air travel risk only. The 9 RCTs,
described in Table 3, ranged in size from 186
32 to 833
18 and
were performed in 3 countries. All limited investigation to air
travel. Eight of the 9 trials
18,27–33 came from the same group of
investigators.
Methodologic Strengths of the Reviewed Studies
Compliance with the methodologic standards is noted in
Tables 1 through 3. The reviewed studies used strong research
methods to establish VTE diagnosis and to evaluate the
efficacy of preventive interventions. Each of the included
studies used objective diagnostic tests to confirm the VTE
(standard 7, Appendix). Therefore, within the limits of the test
operating characteristics, any reported episode of VTE was in
fact VTE. Each of the preventive interventions was evaluated
with RCTs so that conclusions about treatment efficacy are
less prone to bias.
Methodologic Weaknesses the Reviewed Studies
There were 3 major methodologic weaknesses of the reviewed
studies. Because none of the studies avoided all 3, it was
impossible to precisely determine the risk of travel-related VTE.
First, the 4 largest cohort studies did not undertake routine
VTE surveillance (standard 6, Appendix) but, rather, identified
cases from retrospective reviews of medical records.
10,17,21,23
This strategy leads to a low count of VTE cases, particularly
when PEs but not DVTs are counted and when cases are
sought for a limited time period after travel in a limited number
of medical settings.
10,17,21 As we expected, when cases are
identified from medical records but without limits on time or
setting, a higher count is reported.
23 When routine surveil-
lance with lower extremity ultrasound is used, as occurred
with most of the cohort studies and all of the controlled trials,
there are many more VTE cases identified, mostly asymptom-
atic DVTs. Our multivariate analysis, controlling for travel
duration and clinical risk, found that the OR for screening
ultrasound–diagnosed VTE was 390 compared to VTE diag-
nosed through usual clinical care (Table 4).
Second, many of the studies were prone to volunteer bias.
While 4 studies enrolled consecutive series or sampled the
entire population,
10,17,21,23 most studies enrolled volunteers
who tend to be healthier than nonvolunteers.
34 In addition,
volunteer bias works to compound the “healthy traveler effect,”
providing an explanation for why the baseline risk of VTE in
travelers is less than that of the general population.
23
Third, outcome measures varied among studies. Some
studies looked only for DVTs, others only for PEs, and others
for all VTEs (i.e., both DVTs and PEs). As we expected, there
were more frequently reported outcomes when DVT was
included than when the outcome was PE alone [OR 23 and
21, respectively, for DVT and all VTE compared to PE alone
(Table 4)].
Clinical Findings: Risk of Travel-Related VTEs
The cohort studies and the control groups of the RCTs provide
information about the incidence of VTE after travel. These
studies looked only at air travel and report a wide range of VTE
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19,24,29 to 12% of travelers.
26 As expected,
studies of symptomatic VTE patients reported lower rates of
VTE, about 0.5 PEs per million travelers presenting in the
airport on the day of arrival
10,17,21 and 27 VTEs (both PE and
DVT) per million travelers presenting within 14 days of
travel.
23
The studies performing ultrasound surveillance found
much higher VTE rates in travelers, 1.2% DVT (44/3,820,
ranging from 0 to 12%). Of note, all subjects were proven by
ultrasound before embarkation to be DVT-free. One third of the
reported DVTs were in proximal veins, and two thirds were in
calf veins. However, only 2 of the 44 ultrasound-positive
patients had symptoms. Therefore, the overall rate of symp-
tomatic DVT was 0.05%, but with a wide 95% confidence
interval (0.01% to 0.19%). One study screened travelers with
the D-dimer test followed by 3 months of surveillance for VTE
symptoms and reported a cumulative VTE rate of 1.0%, with 5
of 9 cases symptomatic.
22
Two cohort studies included nontraveling control
groups.
19,20 Although no statistically significant difference in
VTE rates between travelers and nontravelers was found, in
one of these studies there was a trend toward a higher DVT
rate in the travelers (0.7% vs 0.2% in nontravelers, P=NS).
20
A travel dose–response curve is demonstrated in individual
studies
17,21 and confirmed by our multivariate model (Table 4).
Symptomatic PE is almost unheard of for flights of less than
6 hours
17,21 [OR of 0.011 compared to flights of 6–8 hours
(Table 4)], but flights of more than 8 hours have increased risks
(OR for VTE of 2.3 compared to flights of 6–8 hours).
In addition to flight duration, our multivariate analysis
found that a higher clinical VTE risk was associated with
higher VTE rates (Table 4). Nine studies
17,20–22,26,27,30–32
reported the following risk factors in 126 VTE patients: age
over 40, 45%; female hormone use, 31%; varicose veins, 19%;
obesity, 17%; inherited clotting disorder, 6%; and other
factors, 7%. None of these studies compared rates of DVT risk
factors in VTE subjects with those of non-VTE subjects.
Despite the publicity surrounding “economy class syndrome,”
no study compared the seating of VTE subjects (first class or
not, aisle seating or not) with that of non-VTE subjects.
Only the case-control studies examined the risk of travel
modes other than air, and only air travel was associated with
VTE.
11–15
Clinical Findings: Prevention
Table 3 lists the studies that evaluated preventive interven-
tions, all RCTs. All subjects, whether in a control arm or an
intervention arm, were encouraged to exercise and maintain
good hydration during flight. The interventions tested were
low-molecular-weight heparin (LMWH), aspirin, graduated
compression stockings, and herbal remedies with putative
antithrombotic properties. Only 1 study
30 evaluated LMWH
(enoxaparin) and found a trend favoring effective DVT pre-
vention that did not reach statistical significance. The same
study found no effect from aspirin. No studies tested warfarin
or unfractionated heparin. Graduated compression stockings,
ranging from 12 mmHg to 30 mmHg at the ankle, were eval-
uated in 6 studies, and 4 of these studies reported a statis-
tically significant benefit.
18,26,27,31 Of the 1,237 subjects using
compression stockings, only 2 DVTs were found (0.2%), com-
pared to 46 in the 1,245 controls (3.7%). Two studies
32,33 eval-
uated preparations containing pycnogenol, an extract of pine
bark with antioxidant and possible antithrombotic effects,
35
with 1 study reporting fewer DVTs among treated passengers.
32
DISCUSSION
We conclude that there is a risk of symptomatic VTE from
prolonged air travel. Our estimate of the magnitude of this risk
varies according to study methodology. If we depend on VTE
rates identified through usual clinical care, the risk may be as
low as 27 cases per million travelers [number needed to harm
(NNH)=38,000].
23 This estimate, equivalent to 1.1 VTE per
million person-days and incorporating the healthy traveler
effect while avoiding volunteer bias, is close to but less than
the baseline risk in general populations, estimated to be 1.9 to
5.2 VTE per million person-days.
23,36–40
If we depend on ultrasound screening studies, the overall
VTE risk may be as high as 1.2%. However, in contrast to symp-
tomatic travel-related PE, little is known about the natural
history of asymptomatic travel-related DVT. We believe that
most asymptomatic thrombi resolve without treatment but that
some progress to symptomatic DVTs and PEs during the several
weeks after travel.
7,41,42 Therefore, the rate of clinically impor-
tant travel-related VTEs must be less than the rate found by
screening ultrasound studies. Counting only symptomatic
DVTs, 0.05% is a more likely estimate of the incidence of clin-
ically important DVTs from prolonged air travel. Assuming none
of these travelers would have developed DVTs if they had stayed
home, the NNH would be 2,000.
VTE risk is very low when flight time is less than 6 hours,
but is progressively greater with longer-duration flights.
However, the overall VTE risk is still much lower than what is
considered the “low-risk” category in surgical patients (2% calf
DVTs, 0.4% proximal DVTs, and 0.2% clinical PEs).
43 The odds
of VTE after long flights (>8 hours) and for higher-risk travelers
(Table 4) are slightly greater than those reported for “weak”
VTE risk factors (e.g., bed rest more than 3 days, increasing
age, laparoscopic surgery, obesity, antepartem pregnancy, and
varicose veins) and similar to those reported for “moderate”
Table 4. Logistic regression model evaluating association
of clinical and study methodology factors with VTE
Variable OR 95% CI P
Screening method
Usual clinical care 1.0*
Screening ultrasound 390 200–761 <0.0001
VTE outcomes reported
PE only 1.0
DVT only 23 10–52 <0.0001
All VTE (PE and DVT) 21 16–27 <0.0001
Mean travel duration
Less than 6 h 0.011 0.0019–0.11 <0.0001
6–8 h 1.0
More than 8 h 2.3 1.4–3.6 <0.0001
Clinical VTE risk
†
Lower 1.0
Higher 3.6 2.2–5.8 <0.0001
P compared to reference category.
VTE venous thromboembolism, DVT deep venous thrombosis, PE pulmo-
nary embolism, OR odds ratio, CI confidence interval.
*Reference category.
†See Table 2 for description of risk categories.
112 Philbrick et al.: Air Travel and Venous Thromboembolism JGIMrisk factors (e.g., arthroscopic knee surgery, congestive heart
failure, hormone replacement therapy, stroke, postpartum
pregnancy, previous thromboembolism, antithrombin deficien-
cy, proteins C and S deficiencies, prothrombin G20210A, and
heterozygous factor V Leiden).
44,45 They are much less than
those reported for “strong” risk factors (e.g., hip fracture, joint
replacement, major trauma, spinal cord injury, oral contra-
ceptives plus factor V Leiden, and homozygous factor V
Leiden).
44,45 Healthy travelers without VTE risk factors other
than travel do not need to worry about VTE from prolonged air
travel. However, travelers with VTE risk factors are at
increased risk directly related to the importance of their risk
factor(s) and the duration of their flight.
In addition to exercise and hydration for all travelers, com-
pression stockings are helpful for long-haul travelers. LMWH
does not have established efficacy, and none of the reviewed
studies evaluated warfarin and unfractionated heparin. How-
ever, the efficacy of LMWH, unfractionated heparin, and war-
farin for VTE prophylaxis has been established in other
settings.
43 If compression stockings could not be used or if ad-
ditional preventive measures were thought to be needed, we
believe that various proven anticoagulant regimens (e.g., low-
dose unfractionated heparin bid or tid; LMWH qd or bid) could
be adapted to prolonged air travel, including the one used by
Cesarone et al.
30 We favorthe use of compression stockings over
anticoagulants because the number needed to treat is likely
more than 2,000 and there is some risk, although small, from
anticoagulant use. Because aspirin is ineffective in other DVT
prophylaxis settings, we were not surprised that the evidence
available in this review did not suggest an aspirin benefit. We do
notrecommendpycnogenolpreparationsatthistime,duetothe
limited data on its properties.
The decision regarding VTE prophylactic measures in long-
distance air travelers should be made in a manner analogous
to other decisions regarding VTE prophylaxis—according to the
degree of risk. Unfortunately, in contrast to surgery, risk levels
for air travel are not well defined for the clinical conditions as-
sociatedwithincreased VTErisk. We makethe followingspecific
recommendations:
1. All air travelers should avoid dehydration and frequently
exercise their leg muscles in their seats, as well as by
walking in the aisle when possible.
2. Travelers with no known risk factors for VTE, regardless of
the duration of the flight, have such a low risk of VTE that
additional prophylactic measures are not necessary.
3. If, in a physician’s judgment, prophylactic measures are
warranted because a traveler has sufficiently increased
VTE risk, knee-high graduated compression stockings,
15–30 mmHg at the ankle, have proven efficacy and
should be recommended for flights longer than 6 hours.
4. LMWH, while neither proven nor disproved in this setting,
can be used if graduated compression stockings are not an
option or if VTE risk seems especially high.
As always, further research is needed; for example: evalu-
ation of the VTE risk of travel (including the healthy traveler
effect) using study methodology that avoids volunteer bias,
screens for both PE and DVT, includes an assessment of VTE
symptoms, and follows travelers for a sufficient time after
arrival; evaluation of the clinical importance of asymptomatic
DVT after prolonged travel; further investigation of the addi-
tional risk conferred by air travel on travelers with 1 or more
VTE risk factors, including whether seating location is a risk
factor; derivation and validation of a decision rule for VTE
prophylaxis for air travel; further investigation of the VTE risk
of other travel modalities; and further investigation of the
effectiveness of other preventive measures including LMWH
and unfractionated heparin.
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APPENDIX
Description of methodologic standards
Standard 1: Adequate description of the subject assembly
process. (a) Methods for patient selection should be described
in enough detail that the study could be replicated with a
similar group of patients. (b) The number of eligible but not
enrolled subjects, as well as any reasons for exclusion, should
also be reported.
Standard 2: Adequate description of subjects. Summary
demographic information (gender, age), as well as type and
duration of travel, should be reported.
Standard 3: Equality of comparison groups. RCT should not
only employ random allocation to treatment modality but also
demonstrate that the treatment groups were similar in terms
of demographics (age and sex) and duration of travel. In cohort
studies with control groups, both demographic characteristics
and VTE risk should be similar between groups; if not,
statistical adjustment for differences should have been
performed. In case-control studies, the cases and controls
should be matched for age, sex, and at least 1 VTE risk factor;
otherwise, statistical adjustment should take these variables
into account. With the exception of travel history, cases and
controls should be enrolled using the same selection criteria.
Standard 4: Adequate reporting of subject follow-up. The
number of patients unavailable for outcome or exposure ascer-
tainment should be reported, as well as the reasons why this
information was not available.
Standard 5: Adequate description of treatment. Treatment
should be described in enough detail so that other subjects
could be treated in a similar fashion.
Standard 6: Unbiased surveillance for adverse outcomes and
determination of exposure. For cohort and RCT studies, either
objective VTE test results or systematic survey for travel-
related VTE symptoms should be reported. For case-control
studies, travel exposure should be ascertained in the same
fashion for cases and controls, including use of measures that
would limit recall bias.
113 Philbrick et al.: Air Travel and Venous Thromboembolism JGIMStandard 7: Adequate VTE diagnostic evaluation. Any diag-
noses of DVT or PE should be based on objective test results.
Standard 8: Analysis that takes type and duration of travel into
account. VTE risk should be adjusted by travel type and
duration.
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